The Kinetics of Anti-HLA Antibodies in the First Year after Kidney Transplantation: In Whom and When Should They Be Monitored?

Table 2

Clinical outcomes according to pretransplant PRA.

	Group A	Group B	Group C
	PRA = 0	PRA > 0 no DSA	PRA > 0 with DSA
	N (89) = 59.3%	N (39) = 26%	N (22) = 14.7%
Acute rejection	12/89 (13.5%)	10/39 (25.6%)	8/22 (36.4%)	<0.001
(i) ABMR	0 (0%)	4 (40%)	8 (100%)	<0.001
(ii) TCMR	12 (100%)	6 (60%)	0 (0%)	<0.001
Graft Loss	1/12 (8.3%)	1/10 (10%)	1/8 (12.5%)	0.999
Death	0/12 (0%)	0/10 (0%)	1/8 (12.5%)	- - - -

PRA: panel reactive antibody; DSA: donor specific antibody; ABMR: antibody-mediated rejection; TCMR: T-cell mediated rejection.